The company enlisted the support of TransPerfect to provide a medical writer with expertise in the genetic disease to transcribe the meeting in full and produce an executive summary detailing the main takeaways and discussions....
We all know there is a significant increase in data collected from wearable sensors, but what does that mean for eCOA? In our latest whitepaper , Mark Wade, Global Practice Leader for TransPerfect Life Sciences examines the considerations of adopting these sensors as an addition to the typical Clinical Outcome Assessment (COA) tools used routinely today. What are the impacts on a study team? What are the considerations in selecting these modalities? Consumer grade vs....
Patients are, at last, gaining a voice in healthcare. Stakeholders have come to recognize that patients have valuable information to share about their experiences with diseases and medications that should influence policy and treatment decisions. The U.S. Food & Drug Administration (FDA), for example, has launched an initiative, “The Voice of the Patient,” to gather patient perspectives across specific disease areas. Information reported by clinical trial participants...
The rush to a vaccine has accelerated an already dynamic research process. This has led to many innovations and an evolution of procedures. The language translation industry has seen enormous stressors and has had to create and modify processes and technologies similarly. The pandemic has changed society profoundly. The disruption in human and business interactions have not only affected the travel, conference, and hospitality industries but has also changed the clinical...
In order to ensure a fluid experience for a patient, usability testing is a critical data point to consider. Addressing both a patient’s needs and access to a digital platform is key to data collection. TransPerfect, along with our partners from Parexel, Clinical Ink, and Health Psychology Research, recently published a poster at the Virtual ISPOR Europe 2020 conference that reviews the impact of moving from in-person to electronic data collection....
Writing a scientific manuscript involves considerable planning and organization to boost your chances of publication in a peer-reviewed journal. Here, we show you how to develop a thorough plan to present research logically and how to avoid the common pitfalls of authorship, so you can overcome the chances of rejection for publication....
Selecting and deploying a new eCOA solution involves many important factors - from determining the capabilities of the Language Service Provider (LSP) to identifying the technology used for each COA migration - and it’s impossible not to worry about missing a key detail in the process. Download our whitepaper to learn about the eCOA landscape today, and access a checklist that walks through each of the essential factors to consider so you can be confident your eCOA...
Our checklist overviews 10 essential factors to consider when implementing MT for your life sciences content, so you can leverage the benefits of increased quality, reduced costs, and shortened turnaround times this technology offers....
Patient recruitment (PR) is a layered, complex endeavor. It is not just placing social media advertisements, nor is it just emailing as many patients and sites as possible. It is a holistic, systematic process that can be the single biggest stumbling block of an entire study. Many will say it is costly, but the cost of not doing it correctly is enormous. Download our paper to learn more about the dynamics of patient recruitment and access a checklist that can help guide...
Over the past decade, the global clinical trial landscape has changed drastically. A surge in technological innovation, including wearable devices, patient portals, and apps, has modernized how clinical data is collected and managed. With pen and paper becoming obsolete in the digital era, shifting to electronic Clinical Outcome Assessments (eCOAs) is becoming more critical than ever. However, it is imperative that the migration of COAs to an electronic format is error...
As pharmaceutical companies implement one or more Veeva Vault applications, it is important to consider the global aspect of content. Download our simple checklist to see if your organization could benefit from a connector between Veeva Vault and a TMS....
App localization can be a complex process, especially for life sciences organizations. With many apps designed with patient experience in mind, such as patient portals designed for the collection of health data and tracking patient journeys, it's critical that internationalization (i18n) is also taken into account. Download our seven considerations for key insights into improving and optimizing your app localization process to ensure you are not only accounting for...
Join your industry peers for Conversations on Clinical Content, C3 Summit. Panels of pharma, biotech, CRO, and regulatory thought leaders will explore patient diversity, centricity, and outcome assessments, discussing challenges, opportunities, and strategies through the lens of real-world experience. Take away practical insights and participate in a discussion during the Q&A and post-event cocktail hour. ...
Join your industry peers for Conversations on Clinical Content, C3 Summit. Panels of pharma, biotech, CRO, and regulatory thought leaders will explore patient diversity, centricity, and outcome assessments, discussing challenges, opportunities, and strategies through the lens of real-world experience. Take away practical insights and participate in a discussion during the Q&A and post-event cocktail hour. ...
Join your industry peers for Conversations on Clinical Content, C3 Summit. Panels of pharma, biotech, CRO, and regulatory thought leaders will explore patient diversity, centricity, and outcome assessments, discussing challenges, opportunities, and strategies through the lens of real-world experience. Take away practical insights and participate in a discussion during the Q&A and post-event cocktail hour. ...
Part 1: What is a CCMS and How Does It Address the Challenges Posed by MDR and IVDR?...
Part 2: What is a CCMS and How Does It Address the Challenges Posed by MDR and IVDR?...
Part 3: EnCompass Step by Step: A Detailed View of the Content Automation Solution to Meet MDR & IVDR Requirements...
This electronic clinical outcome assessment (eCOA) webinar will explore the latest advancements in wearable technology and their potential to improve patient data collection in clinical studies. While there may still be ongoing discussions around deployment and standardization, it is clear that newer technologies such as accelerometers and video have the ability to passively or proactively gather more patient data. These wearable devices offer significant advantages in terms...
Part 1: Clinical Trials and COVID-19: Situation Now, its challenges, and the Future The novel COVID-19 virus has forced a lot of rapid changes in a very short period. Personally and professionally, we are all learning how to adapt. While restrictions on our day-to-day lives impact where, why, and how we interact, we still can come together as a community to learn, grow, and overcome. TransPerfect Life Sciences hosted Part 1 of the Clinical Trials and COVID-19 webinar...
Download your copy of our Plain Language Summaries Checklist....
Please complete the form below to access the on-demand recording of our webinar. A fantastic expert panel of life sciences dealmaking veterans from AstraZeneca and Merck, with 100 years' collective experience, share their insights on key dealmaking strategies, best practices, and common pitfalls to avoid in order to maximise value and mitigate risk in life sciences dealmaking, and also answer audience questions. Topics discussed include: - The importance of...
As the most significant change in the European Union clinical trial legislative ecosystem in 20 years, the European Union Clinical Trial Regulation 536/2014 (EU CTR) went live on January 31, 2022. The first-year transition period has now ended, and from January 31, 2023, EU Clinical Trial Regulation became compulsory for all new interventional clinical trials of investigational medicinal products. All ongoing trials approved under the previous regulatory framework (EU...
